A detailed history of Everence Capital Management Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Everence Capital Management Inc holds 11,650 shares of RGNX stock, worth $88,773. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,650
Previous 11,450 1.75%
Holding current value
$88,773
Previous $176,000 30.68%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$10.49 - $14.39 $2,098 - $2,878
200 Added 1.75%
11,650 $122,000
Q3 2023

Oct 16, 2023

BUY
$16.46 - $19.99 $188,467 - $228,885
11,450 New
11,450 $188,000
Q4 2021

Jan 28, 2022

SELL
$30.19 - $40.28 $155,176 - $207,039
-5,140 Closed
0 $0
Q3 2021

Oct 21, 2021

BUY
$29.09 - $45.68 $149,522 - $234,795
5,140 New
5,140 $215,000
Q1 2021

Apr 06, 2021

SELL
$33.61 - $49.95 $172,755 - $256,743
-5,140 Closed
0 $0
Q4 2020

Feb 01, 2021

BUY
$26.52 - $49.35 $136,312 - $253,659
5,140 New
5,140 $233,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Everence Capital Management Inc Portfolio

Follow Everence Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.